Quantcast
Last updated on April 16, 2014 at 5:23 EDT

Latest Transplant rejection Stories

Bioengineered Implantable Rat Kidney Created At Massachusetts General Hospital
2013-04-15 06:17:09

redOrbit Staff & Wire Reports - Your Universe Online Scientists have successfully bioengineered a kidney and implanted it into a living creature — work which could be an important step forward in the search for personalized replacement organs that could be transplanted into patients with kidney failure, according to media reports published Sunday. According to Alok Jha, science correspondent with The Guardian, Dr. Harald Ott of the Center for Regenerative Medicine at...

2013-03-01 11:59:52

Steroids do not prevent this antibody-mediated injury and rejection Highlights: -Pediatric kidney transplant recipients who have antibodies directed against their new organ are more likely to experience kidney injury and rejection than patients without these antibodies. -Steroids do not prevent this antibody-mediated injury and rejection. -Approximately 2,500 children received a kidney transplant last year in the United States. A transplanted kidney has a finite life expectancy...

2013-02-15 20:21:09

EAST HANOVER, N.J., Feb. 15, 2013 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) has approved Zortress(®) (everolimus) for the prophylaxis of organ rejection in adult patients receiving a liver transplant. Zortress is the first mammalian target of rapamycin (mTOR) inhibitor approved for use following liver transplantation. It is also the first immunosuppressant approved by the FDA in over a decade for use following liver transplantation.(1 )...

2013-01-28 14:14:29

A new study from Boston University School of Medicine (BUSM) shows that tissues derived from induced pluripotent stem (iPS) cells in an experimental model were not rejected when transplanted back into genetically identical recipients. The study, published online in Cell Stem Cell, demonstrates the potential of utilizing iPS cells to develop cell types that could offer treatment for a wide range of conditions, including diabetes, liver and lung diseases, without the barrier of immune...

2013-01-03 08:23:25

HORSHOLM, Denmark, Jan. 3, 2013 /PRNewswire/ -- Veloxis Pharmaceuticals A/S today is announcing that the LCP-Tacro Phase III clinical trial in stable kidney transplant patients, the 3001 study, has been published online in the American Journal of Transplantation. The article reports on the randomized, controlled, multicenter Phase III trial, which demonstrated that LCP-Tacro dosed once-daily was not inferior to the current leading transplant drug, Prograf(®), dosed twice-daily....

2012-12-26 16:20:44

A combination of three blood-borne proteins may bolster efforts to prevent graft loss years after transplant BOSTON, Dec. 26, 2012 /PRNewswire-USNewswire/ -- Researchers at Boston Children's Hospital have found a combination of biomarkers related to blood vessel and tissue injury that, when measured together, could signal when a transplanted heart is becoming damaged to the point of failure, a process that is often undetected. The markers would give doctors an opportunity to intervene...

2012-11-16 11:42:59

Findings could help provide better donor-recipient matches and tailor recipients' treatments after kidney transplantation Highlights: -The detection of preformed donor-specific antibodies by newer tests, despite negative results from traditional tests, nearly doubles a kidney transplant recipient's risk for rejection. -It also increases the risk of kidney failure by 76%. Nearly 17,000 kidney transplants take place each year in the United States. Kidney transplant recipients who...

2012-10-10 07:28:02

HORSHOLM, Denmark, Oct. 10, 2012 /PRNewswire/ -- Veloxis will give two upcoming data presentations that further define the profile of LCP-Tacro compared to other tacrolimus formulations. The first study demonstrates the potentially flexible dosing that may improve dosing convenience for transplant patients. A second study demonstrates the enhanced bioavailability of tacrolimus driven by LCP-Tacro's proprietary formulation, compared to another once-daily tacrolimus formulation, which could...

2012-09-24 06:26:59

NORTHBROOK, Ill., Sept. 24, 2012 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for tacrolimus extended release capsules for the prophylaxis of organ rejection in adult kidney transplant recipients and adult male liver transplant recipients. Developed by Astellas, tacrolimus...

2012-09-12 06:31:55

ALEXANDRIA, Va., Sept. 12, 2012 /PRNewswire/ -- Oxford Finance LLC ("Oxford"), a specialty finance firm that provides senior debt to life sciences and healthcare services companies, today announced a $15 million round of debt financing for XDx, Inc. Silicon Valley Bank acted as co-lender in this transaction. Proceeds of the loan will be used for working capital and to fund the development of new diagnostic applications using XDx's molecular expression technology. "XDx is a pioneer in the...